Atricure, INC Form 4 insider transactions

AtriCure's Chief Marketing & Strategy Officer, Justin Noznesky, reported a charitable gift of 585 common stock shares.

Deborah Lee Yount, Chief Human Resources Officer at AtriCure, Inc., reports the disposal of shares to cover tax obligations related to vested restricted stock awards.

Director Maggie Yuen sold 3,500 shares of AtriCure, Inc. (ATRC) at a price of $24.07 on August 15, 2024.

AtriCure's CEO, Michael Carrel, reported a charitable gift of 3,000 common stock shares and disclaims beneficial ownership of shares held by his children and parents.

Douglas J. Seith, Chief Operating Officer of AtriCure, Inc., acquired 707 shares of common stock through the company's Employee Stock Purchase Plan at a price of $19.35 per share.

Chief Legal Officer Karl S. Dahlquist acquired 707 shares of AtriCure, Inc. through the company's Employee Stock Purchase Plan (ESPP) at a discounted price of $19.35 per share.

AtriCure's CEO, Michael Carrel, acquired 707 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a discounted price of $19.35 per share.

AtriCure's Chief Technical Officer, Salvatore Privitera, acquired 707 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a discounted price of $19.35 per share.

Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., acquired 707 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) on June 28, 2024.

Deborah Lee Yount, Chief Human Resources Officer at AtriCure, Inc., acquired 707 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) on June 28, 2024.

Salvatore Privitera, Chief Technical Officer of AtriCure, Inc., recently purchased 5,000 shares of the company's common stock.

Director Robert S. White acquired 7,788 shares of AtriCure, Inc. through a restricted stock award, vesting in one year.

Director Maggie Yuen reports acquiring 7,788 shares of AtriCure common stock through a restricted stock award and disposing of 12,470 shares.

Director B. Kristine Johnson acquired 7,788 shares of AtriCure, Inc. through a restricted stock award, which will vest in one year.

Director Regina E. Groves acquired 7,788 shares of AtriCure, Inc. common stock through a restricted stock award.

Director Deborah H. Telman reports acquisition of 7,788 shares of AtriCure, Inc. through a restricted stock award and disposal of 16,783 shares.

Director Sven Wehrwein acquired 7,788 shares of AtriCure, Inc. through a restricted stock award that vests in one year.

Director Karen Prange acquired 7,788 shares of AtriCure, Inc. through a restricted stock award that vests in one year.

Director Shlomo Nachman acquired 7,788 shares of AtriCure, Inc. through a restricted stock award, with vesting occurring one year from the grant date.

Justin J. Noznesky, Chief Marketing & Strategy Officer of AtriCure, Inc., sold 1,500 shares of common stock at $24.09 per share on May 1, 2024, under a pre-arranged 10b5-1 trading plan.

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 1,500 shares of common stock on April 1, 2024, at a price of $30.39 per share, according to a Form 4 filing with the SEC.

Karl S. Dahlquist, Chief Legal Officer of AtriCure, Inc., sold 1,885 shares of common stock at $32.16 per share on March 18, 2024, under a pre-arranged 10b5-1 trading plan.

AtriCure's CEO, Michael Carrel, reported a gift of 2,000 shares of common stock to his children on March 14, 2024, according to a Form 4 filing with the SEC.

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 1,500 shares of common stock at $36.72 per share on March 12, 2024, under a pre-arranged 10b5-1 trading plan.

Karl S. Dahlquist, Chief Legal Officer of AtriCure, Inc., sold 8,231 shares of common stock on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Deborah Lee Yount, Chief Human Resources Officer at AtriCure, Inc., reports acquisition of shares through a restricted stock award and disposition of shares to cover tax obligations.

AtriCure's CEO, Michael Carrel, reports acquisition and disposal of company stock, including shares from restricted stock and performance share awards.

AtriCure's Chief Financial Officer, Angela Wirick, reported the acquisition and disposal of company stock and the exercise of stock options on March 1, 2024.

AtriCure's Chief Legal Officer, Karl S. Dahlquist, reports acquiring shares through a restricted stock award and the vesting of a performance share award.

AtriCure's Chief Operating Officer, Douglas J. Seith, reports acquisition and disposal of company stock, including shares from restricted stock and performance share awards.